Moonwalk Biosciences raises $70M Series B to push MW-101, an siRNA obesity drug aimed at fat tissue, toward a 2027 trial start.
Moonwalk Biosciences is heading to the clinic with an obesity program and has raised $70 million for that goal, leaning into a shift in its …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
The California biotech plans to bring its first drug, enabled by licensing technology from a Chinese drugmaker, into clinical…
Superluminal Medicines raises $60M Series B for Phase 1 trials of MC4R obesity drug, backed by investors including Eli Lilly, RA…
For $190 million up front and as much as $2.3 billion overall, the Swiss drugmaker is building its portfolio with a shot that…
Roche licenses Hanmi Pharm's non-incretin obesity drug HM17321 in a deal worth up to $2.3B, including $190M upfront.
Ractigen Therapeutics Announces ADA 2026 Late-Breaking Presentation Highlighting saRNA as a New Frontier in Obesity Control
Signos, a startup that aims to help people lose weight by understanding their blood sugar, has raised a new $20 million round of…
